Craig Bijou

Vikramjeet Chopra

Jayson Bedford

Joanne Wuensch

Matthew Taylor

Richard Newitter

Robert Marcus

Ryan Zimmerman

Steven Lichtman

Young Li

Anthony P.

Izzy G.

Kristen Stewart

Lilia-Celine Lozada

Lilly Z.

Ravi M.

Ravi Misra

Vik Chopra

- Integra LifeSciences updated its **2025 gross margin guidance** in Q2, now expecting a decline of **300 basis points** versus 2024, an additional **100 basis points** compared to Q1 expectations, primarily due to costs from the **MetaHunting product recall**.  **[917520_tx_381237_2]** 
- The company has launched a **profitability initiative** aiming for **$25 million to $30 million** in annualized savings by **2026**, focusing on operational improvements and OpEx management, with P&L impact expected in the **second half of 2026**.  **[917520_tx_381237_0]** **[917520_tx_381237_3]** 
- Management expects **2025 to be the peak year for ship hold impact** and anticipates **growth in 2026** driven by strengthened quality management systems, increased supply reliability, and the benefits of the margin expansion program.  **[917520_tx_381237_4]** 
- Near-term capital allocation priority remains **debt reduction**, with leverage at **4.5 times** at the end of Q2 2025, within the **5x** maximum allowable ratio.  **[917520_tx_381237_7]**  M&A is not a near-term priority.  **[917520_tx_381237_7]** 
- Key growth drivers for the next two to three years include **stabilizing supply**, reintroducing **Primatrix and Surgemend** (with Braintree facility operationalization targeted for **2026**), and **international expansion**.  **[917520_tx_381237_6]** **[917520_tx_381237_8]**

Integra LifeSciences Discusses Operational Challenges, Financial Outlook, and Growth Drivers

INTEGRA LIFESCIENCES HOLDINGS (IART)